Earlier this week, we highlighted an opportunity in Moderna (MRNA).
At the time, it traded at just $33.95. It’s now up to $37.25, and could push to $40, near-term.
“Moderna’s Covid-19 vaccine, which has drawn enormous attention in recent months, is among nine experimental prophylactic vaccines the company is developing. All of the vaccines employ the same approach, in which small bits of messenger RNA are used to activate the immune system against a particular virus,” reports Barron’s.
According to the company, the first participant has been dosed in the Phase 1 study of the Company’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2). This Phase 1 study is being conducted by the National Institutes of Health (NIH) under its own Investigational New Drug (IND) application.
However, it’s not the only opportunity on the market.
As more people work from home, stocks like Slack Technologies (WORK) are gaining traction.
Cantor Fitzgerald analysts also see opportunity, noting: “We believe the company and platform have a number of unique, positive attributes, including its ability to drive customer productivity and efficiency, applicability across all industries and business sizes, and a growing ecosystem to facilitate seamless integration,” notes the firm, as quoted by Barron’s. “We expect these attributes to lead to increased market penetration and margin expansion and believe these characteristics will allow the company to expand its multiple.”
At the moment, shares of WORK are up to $28.13 and could race to $35, near-term.